Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) has shared an update.
Shareholders of Lee’s Pharmaceutical Holdings Limited approved all 10 resolutions at the company’s annual general meeting held on 21 May 2026, including the adoption of the 2025 audited financial statements and the declaration of a final dividend. Investors also backed the re-election of directors across executive, non-executive and independent non-executive roles, authorised the board to set directors’ and auditors’ remuneration, re-appointed Confucius International CPA Limited as auditor, and granted share repurchase and issuance mandates, reinforcing management’s financial and capital-raising flexibility.
The AGM resolutions passed with strong majorities, with most items receiving near-unanimous support from votes cast. The approval of general mandates to issue and repurchase shares, along with the extension of the issuance mandate, provides the company with tools to manage its capital structure and pursue potential financing or strategic opportunities, while the confirmed board composition and auditor re-appointment signal continuity in governance and oversight for shareholders.
More about Lee’s Pharmaceutical Holdings Limited
Lee’s Pharmaceutical Holdings Limited is a Hong Kong-listed pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical products. The group focuses on prescription drugs and related healthcare products, serving hospital and specialist markets in Hong Kong, mainland China and other regions.
Average Trading Volume: 744,855
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$653.6M
See more insights into 0950 stock on TipRanks’ Stock Analysis page.